Table 2.
ARID1A mutations in solid carcinomas
| Cancer type | Mutational rate | Reference(s) |
|---|---|---|
| Breast cancer | 3.2% (3/95) | Cornen et al63 |
| 3.5% (4/114) | Jones et al38 | |
| 0% (0/82) | Mamo et al64 | |
| Colorectal carcinoma | 10.1% (12/119) | Jones et al38 |
| Esophageal adenocarcinoma | 9.1% (1/11) | Agrawal et al40 |
| 15% (3/20) | This paper | |
| Gastric adenocarcinoma | 10% (10/100) | Jones et al38 |
| 27.2% (6/22) | Wang et al32 | |
| 8% (9/110) | Zang et al41 | |
| Hepatocellular carcinoma | 10% (12/120) | Fujimoto et al65 |
| High-grade serous ovarian carcinomas | 0% (0/76) | Wiegand et al39 |
| Lung carcinoma | 5.6% (2/36) | Jones et al38 |
| Ovarian clear cell carcinoma | 57% (24/42) | Jones et al20 |
| 46.2% (55/119) | Wiegand et al39 | |
| Ovarian endometrioid carcinoma | 30.3% (10/33) | Wiegand et al39 |
| Pancreatic ductal adenocarcinoma | 6.9% (2/29) | Birnbaum et al66 |
| 8.4% (12/119) | Jones et al38 | |
| Prostate carcinoma | 8.7% (2/23) | Jones et al38 |
| Transitional cell carcinoma of the bladder | 18.6% (18/97) | Gui et al67 |
Abbreviation: ARID1A, AT-rich interactive domain 1A (SWI like).